Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87245 | 0.87 | POLB (0.42) | LMNAMAPK1POLBALDH1A1TSHR | |
| SCHEMBL19755042 | 0.84 | LMNA (0.32) | LMNAMAPK1 | |
| SCHEMBL19755030 | 0.80 | PKM (0.39) | LMNAMAPK1POLBALDH1A1KMT2A | |
| SCHEMBL12662905 | 0.80 | LMNA (0.33) | LMNAMAPK1ALDH1A1TSHR | |
| SCHEMBL17459629 | 0.79 | MEN1 (0.33) | LMNAMAPK1ALDH1A1KMT2A | |
| SCHEMBL17459592 | 0.79 | MEN1 (0.33) | LMNAMAPK1ALDH1A1KMT2A | |
| SCHEMBL17459584 | 0.79 | CTSS (0.32) | LMNAMAPK1TSHRSMN1; SMN2 | |
| SCHEMBL6460378 | 0.79 | TLR4 (0.35) | LMNAMAPK1ALDH1A1 | |
| SCHEMBL9895084 | 0.79 | TLR4 (0.35) | LMNAMAPK1ALDH1A1 | |
| SCHEMBL19339212 | 0.77 | MAPK1 (0.34) | LMNAMAPK1POLBALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003006-B2 | Difluorobenzene derivative and nematic liquid crystal composition using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-7670504-B2 | Nematic liquid crystal composition and liquid crystal display device using the same | DAINIPPON INK & CHEMICALS, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7651630-B2 | Difluorobenzene derivative and nematic liquid crystal composition using the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090200514-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090050843-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20080111107-A1 | Nematic Liquid Crystal Composition And Liquid Crystal Display Device Using The Same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090050843-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | HCN2, TRPV2, TRPV5 | LMNA 2613/4885MAPK1 1332/4885POLB 3254/4885 |
| US-20090200514-A1 | DIFLUOROBENZENE DERIVATIVE AND NEMATIC LIQUID CRYSTAL COMPOSITION USING THE SAME | TRPV2, HCN2, DVL1 | LMNA 2837/4885MAPK1 1849/4885POLB 3735/4885 |
| US-20080111107-A1 | Nematic Liquid Crystal Composition And Liquid Crystal Display Device Using The Same | PIEZO1, KIF20B, VCL | LMNA 1459/4885MAPK1 1619/4885POLB 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.